Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06477952 · ClinicalTrials.gov registry record · Phase 1
DRonabinol Treatment of OSA
A Phase 1 study of Obstructive Sleep Apnea, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06477952: Recruiting Phase 1 study of Obstructive Sleep Apnea, sponsored by VA Office of Research and Development.
NCT06477952 is a Phase 1 study of Obstructive Sleep Apnea that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 120 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06477952, a Phase 1 study of Obstructive Sleep Apnea, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.
Primary Outcome
The change in AHI after two weeks of Dronabinol treatment will be determined from before and after treatment polysomnograms.
Conditions Studied
Interventions
- DRUG Dronabinol
Study Locations (1)
Illinois
- Jesse Brown VA Medical Center, Chicago, IL - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT06477952 shows while recruiting
NCT06477952 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 1 intervention - of which Dronabinol is the first listed.
NCT06477952 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06477952 about?
NCT06477952 is a clinical study titled "DRonabinol Treatment of OSA". This is an open-label trial that tests the effectiveness of Dronabinol in treating obstructive sleep apnea (OSA). All participants will take oral Dronabinol for two weeks. Sleep studies will be conducted before and after treatment to measure OSA severity.
What is the current status of trial NCT06477952?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-08-25. Estimated completion is 2026-12-31.
What conditions does trial NCT06477952 study?
This clinical trial studies the following conditions: Obstructive Sleep Apnea.
What interventions are being tested in trial NCT06477952?
The interventions under investigation include: Dronabinol (DRUG).
Who is sponsoring clinical trial NCT06477952?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06477952 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Sleep Apnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06477952's enrollment target sits among peer trials
120 61st of 155 higher than 92 of 155 other Obstructive Sleep Apnea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obstructive Sleep Apnea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities
RECRUITING · Phase 1
-
Trazodone on OSA Endotypes
RECRUITING · Phase 1
-
Atomoxetine and DAW2022 on OSA Severity
RECRUITING · Phase 1
-
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
RECRUITING · Phase 1
-
Rescue Pharmacotherapy for OSA
RECRUITING · Phase 1
-
Pharmacological Activation of HMN for OSA Aim 2
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI